Titan, backed by the Tata group, is at the top of its portfolio pyramid. While Star Health, Metro Brands and Tata Motors are some of its recent investments. He stuck with Titan and Crisil since 2015. These five stocks account for nearly 77% of his portfolio wealth.
According to Trendlyne data, the great bull’s wealth rose 25% in less than two weeks from August to ₹31,833.77 million. His wealth was all around ₹25,425.88 million in June and with a record of ₹33,753.92 million in March this year.
Of this total, your share is valued at approximately ₹11,086.9 million to Titan, ₹7,017.5 million to Star Health, ₹3,348.8 million to Metro Brands, ₹1,731.1 million to Tata Motors and ₹1,301.9 million to Crisil on August 12, 2022.
Since August 13, 2015, Titan stock emerged as a multi-bagger with an impressive gain of about 655% updated. Crisil, however, has shot up almost 71% in these years.
Star Health and Metro Brands entered the list in December last year. The general health insurer is down more than 23% since its listing day, but has been on a recovery path since July 2022. Meanwhile, footwear firm Metro Brands has advanced more than 76% since its market debut. It invested in Tata Motors in the September quarter of 2020 and since then the stock has risen 217.5%, according to data available with the BSE.
Here are the details of Jhunjhunwala’s involvement in these actions:
– As of June 30, 2022, the market magnate owns 44,850,970 shares or 5.1% of Titan.
– Has 100,753,935 shares or 17.5% of Star Health as of June 30, 2022.
– His stake is 39,153,600 capital shares or 14.4% at the end of the June 2022 quarter.
– While it holds 36,250,000 shares or 1.1% of Tata Motors at the end of the June 2022 quarter.
– Jhunjhunwala’s stake in Crisil is about 4,000,000 shares or 1.1% as of June 30, 2022.
Here’s an overview of BSE’s actions at the moment. Analysts have given an optimistic outlook on some of these stocks going forward:
On the BSE, Titan shares are around ₹2,471.95 each from August 12. The company’s market capitalization is ₹2,19,456.30 million.
The stock is up at least 35.55% on Dalal Street in a year. Actions were around ₹1,823.55 on August 12 last year.
Analysts Richard Liu, Mehul Desai and Sumanyu Saraf of JM Financial in their report said, “Titan had a great post-pandemic start with strong metrics across all key businesses. Sales momentum picked up strongly in jewelry after a weak Q-mar, with “normalized” growth of 23% (3-year CAGR), which is one of the best seen among the consumer categories we track. Many of the conversations in management revolved around recruiting new consumers into the ecosystem in order to build a “funnel for the future.” The resulting growth, better mix, and cost leverage drove even better profitability than we expected “.
They also said, “Given the strength of the segments, management re-emphasized its overall bullish outlook with guidance for jewelery growth of 2.5x over five years, i.e. 20% CAGR over FY22-27E with short-term margin expected in the 12-13% range. It also seems to have established a higher base now, with wearables becoming a major new driver. The same is true of eyewear, where the recent restructuring has delivered good results. We expect the stock to remain strong after this result, but an NTM > 60x. PER seems too rich an entry point to us.”
A 12-month price target has been set by analysts at JM Financial ₹2,620 to Titan.
Star Health and Allied Insurance:
In the BSE, the shares of Star Health are a ₹696.10 each from August 12. The company’s market capitalization is around ₹40,104.98 million.
Star Health made its market debut on December 10 last year. The company launched its IPO from November 30 to December 3 last year at a price range of ₹870 BC ₹900 each. The IPO witnessed sluggish demand as it was not fully subscribed.
Shares are up more than 42% since July this year to date.
HDFC Securities analysts Sahej Mittal, Krishnan ASV, Deepak Shinde and Neelam Bhatia said in their research note, “Capitalizing on an early mover advantage and significant regulatory arbitrage, STARHEAL is positioned as the largest health insurer standalone (FY22: 33% market share), anchored in an extremely strong and highly productive agency-dominated distribution network and a retail-dominated business mix (FY22: ~90% of GDPI). Despite possible regulatory convergence , we believe STARHEAL has significant room to move to a high-quality franchise, which translates into better earnings quality.”
The analysts further said, “Having secured the agency channel, we argue that the company now needs to build a credible banking strategy to maintain its long-term leadership. We expect STARHEAL to deliver revenue/CAGR APAT of 32%/ 38% over FY20-24 and a healthy RoE in the range of 10%/16% in FY23/24 We start with a BUY and a DCF-derived price target of 860 INR (53x AEPS FY24E and 10x P/ABV FY24E).”
On BSE, the company’s shares are around ₹854.30 each. The stock had hit a new 52-week high ₹869 each on Friday. The company’s market capitalization is around ₹23,199.04 million.
Metro Brands shares were listed on the stock exchanges last year on December 21. The IPO had a price range of ₹485 a ₹500 per piece. The 100% book building has been subscribed 3.64 times in the primary market.
Since its listing, shares of Metro Brands have soared more than 76% on the BSE. So far in 2022, the stock has advanced more than 91.5%, making many investors, including Jhunjhunwala, rich.
Akhil Parekh research analyst and Kevin Shah research associate at Centrum said in their report, “Entry into newer geographies, tie-up with international brands (Crocs and Fitflops) along with the structure of variable costs should help the company grow its sales/EBITDA/CAGR PAT. to 34/36/47%, respectively, in FY22-24E. On a low base, we expect volume (number of pairs) to grow at a CAGR of 25% and ASP at 7% over FY22-24E We have increased our EPS estimates by 49% /36% each for FY23/ 24. We maintain our rating on ADD with a target price of Rs 821. We continue to value the stock at 48x FY24E.”
On the BSE, there are shares of Tata Motors ₹477.50 each. The company has a market capitalization of around ₹1,58,586.12 million.
Shares of Tata Motors have risen more than 56% in a year. Actions were around ₹306 on August 12 last year.
Analysts Vivek Kumar and Ronak Mehta of JM Financial in their research note said, “TTMT expects chip shortages to continue with a gradual improvement in CY22. Management has guided for positive EBIT and FCF for in FY23 at JLR driven by continued production recovery, ‘Refocus.’ and continued efforts towards cost efficiency. Global retail demand remains strong with record high orders and low inventory. S ‘expects a favorable mix, sales recovery and cost saving initiatives to support margins and focus on debt reduction (goal of near debt free by FY24) will help balance sheet strength.Furthermore, the portfolio of electric vehicles by Tata Motors is leading the domestic electric vehicle space and by securing strategic investors, it is well poised to capitalize on its initial success.Keep BUY on the March 23 SOTP of INR 550 ( Standalone/JLR rated at 10x /2.5x EV/EBIDTA). Continued semiconductor shortages, lower-than-expected EV adoption, and inherent risk in evolving EV technologies are key. isks”.
Meanwhile, analysts Rishi Vora and Eswar Bavineni of Kotak Institutional Equities said, “We have refined our 2023-25E consolidated EBITDA estimates. While the near term may remain volatile for JLR due to of the EU recession risk, we believe the company has done well to improve the structural profitability of the business over the past few years.With the chip situation improving, we believe JLR is well positioned to benefit given its new successful launches and the strong order book. In addition, we believe the domestic CV cycle The recovery will continue as the freight rate continues to strengthen and fleet utilization levels improve. Successful new launches of the company in the domestic ICE PV segment as well as growing consumer demand for EVs continue to be a bright spot. We maintain a BUY rating on the stock with a revised FV of Rs 500 (from Rs 47 0 rupees earlier) as we move into September 2024E (from June 2024E earlier).”
On the BSE, Crisil’s shares are a ₹3,261.60 each. The company has a market capitalization of ₹23,824.25 million.
Crisil shares have risen more than 27% in a year. Actions were around ₹2,566 each last year on August 12.
CRISIL is a leading, agile and innovative global analytics company driven by its mission to make markets work better. It is India’s leading provider of ratings, data, research, analytics and solutions. The company has delivered independent opinions, actionable insights and efficient solutions to more than 100,000 clients.
Disclaimer: The above opinions and recommendations are those of individual analysts or brokerage firms, and not of Mint.
Catch all the latest business news, market news, breaking news events and news updates on Live Mint. Download Mint News app for daily market updates. More Less
Subscribe to Mint newsletters
* Please enter a valid email
* Thank you for subscribing to our newsletter.